Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: Twelve-year outcomes
Open Access
- 31 January 2008
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 58 (2) , 370-375
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Biologic therapies in rheumatology: lessons learned, future directionsNature Reviews Drug Discovery, 2007
- Regeneration of B cell subsets after transient B cell depletion using anti‐CD20 antibodies in rheumatoid arthritisArthritis & Rheumatism, 2006
- Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritisArthritis & Rheumatism, 2006
- Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosisEuropean Journal of Immunology, 2005
- Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopeniaArthritis Research & Therapy, 2004
- Immune reconstitutionBest Practice & Research Clinical Haematology, 2004
- Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritisBlood, 2002
- Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopeniaArthritis & Rheumatism, 2001
- The CAMPATH‐1 antigen (CDw52)Tissue Antigens, 1990
- EULAR register of patients on immunosuppressive drugs.Annals of the Rheumatic Diseases, 1982